Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular basis of pharmacotherapies for cognition in Down syndrome.

Trends in pharmacological sciences - 1 Feb 2010

Gardiner Katheleen J

Abstract excerpt

Intellectual disability in Down syndrome (DS) ranges from low normal to severely impaired and has a significant impact on the quality-of-life of the individuals affected and their families. Because the incidence of DS remains at approximately 1 in 700 live births and the lifespan is now >50 years, development of pharmacotherapies for cognitive deficits is an important goal. DS is due to an extra copy of human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD24 Antigen
Share to Cognition Disorders
Share to Disease Models, Animal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down Syndrome

Share to Oxidative Stress

Share to Receptor, Serotonin, 5-HT1A

Share to Receptors, N-Methyl-D-Aspartate

Source

Open in PubMed Open full text

Identifiers

PMID: 19963286
DOI: 10.1016/j.tips.2009.10.010
PMCID: PMC2815198

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular basis of pharmacotherapies for cognition in Down syndrome.PMID 19963286Read ↗

Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerationsSemantic proximity Read ↗

New Perspectives for the Rescue of Cognitive Disability in Down SyndromeSemantic proximity Read ↗

Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative DisordersSemantic proximity Read ↗

Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.Semantic proximity Read ↗

Down Syndrome: From Understanding the Neurobiology to TherapySemantic proximity Read ↗

Understanding the genetic mechanisms and cognitive impairments in Down syndrome: towards a holistic approach.Semantic proximity Read ↗

Molecular and Cellular Alterations in Down Syndrome: Toward the Identification of Targets for TherapeuticsSemantic proximity Read ↗

Down syndrome--recent progress and future prospectsSemantic proximity Read ↗

Pitfalls and hopes in Down syndrome therapeutic approaches: in the search for evidence-based treatments.Semantic proximity Read ↗

Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways.Semantic proximity Read ↗

Comprehensive Analyses of Molecules with Altered Expression in the Brain of a Mouse Model of Down Syndrome for Identification of Pharmacotherapeutic Targets.Semantic proximity Read ↗

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down SyndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.